Board

Mr. Imasogie is the Co-Founder and Senior Managing Partner of PIPV Capital with over 30 years of experience in the fields of law, finance and business management, healthcare and the pharmaceutical industry. Prior to co-founding PIPV Capital, Osagie conceptualized and established GlaxoSmithKline Ventures in which he led his team in investing GSK R&D non-progressed assets into various companies and/or as the basis of starting new companies. Prior to this role within GSK, Osagie was a Vice President for Product Development Strategy at SmithKline Beecham.

Prior to this role at SmithKline, he was the Founding Senior Vice President for Business Development and General Counsel at Endo Pharmaceuticals. He also previously served as a DuPont Merck Vice President for International Sales and Marketing and General Counsel to DuPont Merck’s International, Manufacturing and Generic Drug Divisions. Osagie has been a serial entrepreneur and has been founder and former CEO and/or Chairman of multiple life sciences companies, including Ilera Healthcare, iCeutica, Churchill Pharmaceuticals, Ception Therapeutics and Trigenesis Therapeutics. Osagie has also been a Corporate Finance Partner in Price Waterhouse and a practicing attorney in a major US Law Firm.

Osagie is active in charitable and community pursuits and served as a member of the Board of the Philadelphia Orchestra and the Philadelphia Museum of Art. Osagie is an Adjunct Professor at the University of Pennsylvania Law School and also served on the Law School’s Board of Overseers. In addition, he is a member of the Board of Trustees of the University of Pennsylvania and served as the Chairman of the Budget & Finance Committee in addition to being a member of the Executive Committee. Osagie is a member of the New York State Bar.

With over 10 years in corporate pharmaceutical business development, strategy & operational leadership, Dr. Odumosu brings a unique combination of experiences from academic, public health and life science organizations. In his role as Ilera Healthcare’s first Chief Operating Officer, Dr Odumosu was a core part of the executive team in establishing and managing Ilera’s business operation’s post license award in 2017 through to profitability. He served as Chief Scientific Officer/EVP Pharmaceutical Division for TerrAscend Corp. Prior to Ilera and Zelira, Dr. Odumosu played a critical role in Iroko Pharmaceutical’s post-clinical development of Zorvolex® Tivorbex® and Vivlodex® through FDA approvals and successful US market commercialization. He received a PhD in Biochemistry and a Master’s in Public Health-Epidemiology and Biostatistics from the Loma Linda University School of Medicine and School of Public Health in Loma Linda, California; and a BS in Biology from Calvin College in Grand Rapids, Michigan. Dr. Odumosu is a World Bank Institute Certified public health professional with global healthcare translational/clinical/epidemiological research and data management experience.

Dr. Donna Gentile O’Donnell, a highly regarded health care executive, most recently (May, 2023) served as special assistant to Dr. Stephen K. Klasko, former president of Thomas Jefferson University and CEO of Jefferson Health, and was senior vice president of the organization's innovation pillar. Under her leadership, Jefferson entered into partnership with Independence Blue Cross to create an entrepreneurs-in-residence program; worked with MIT to implement the "Jefferson Health Hack," a spinoff from the MIT Grand Health Hack; and constructed and opened the Health Design Lab. She led the development and implementation of events, courses and lectures around innovation and entrepreneurship. Earlier in her career, O'Donnell spent nine years as managing director of the Eastern Technology Council and was a limited partner in PA Early Stage Partners. While President of Franklin Health Trust, Dr. O’Donnell led the negotiations for the merger of $50 million of the foundation's assets into the Drexel University College of Medicine. She also served as Deputy Health Commissioner for policy and planning for the City of Philadelphia in the mid-1990s under former Mayor Ed Rendell. She earned her doctorate at The University of Pennsylvania, and is also the author of Provider of Last Resort: The Story of the Closure of the Philadelphia General Hospital. In 2005, Dr. O’Donnell was named by Philadelphia Business Journal as a Woman of Distinction. In 2020, Dr. O’Donnell was inducted as a Fellow into the prestigious Philadelphia College of Physicians. Governor Tom Wolf appointed her to serve on the Commonwealth Universal Research Enhancement (CURE) Board, and she has served on the boards of many non-profits and advisory councils. Dr. O’Donnell is also well known for her mentorship of hundreds of students and aspirational professionals, describing mentorship as “increasingly necessary in this increasingly complex world”.

Tim is the founder and director of Catalyst Corporate, a boutique consulting firm. Mr Slate has a Bachelor of Commerce from the University of Western Australia, is a Chartered Accountant, is an Associate Member of the Governance Institute of Australia and is a Graduate of the Australian Institute of Company Directors. Mr. Slate has over 15 years’ experience providing accounting, secretarial and corporate advice to private and public companies across a variety of sectors. Mr Slate was appointed as Company Secretary on 16 December 2016.

Greg brings extensive experience in the pharmaceutical and biotech sectors both within Australia and interna­tionally. Greg has been involved in the strategic development and commercialisation of a number of products across a range of therapeutic categories. Throughout his near 20 years working in healthcare Greg has built a solid foundation of knowledge across marketing and the entire commercial value chain. His work with Rhythm Biosciences as General Manager led the company through the establishment of the pre-launch critical pathway and commercialisation planning for both domestic and international markets. As Regional Marketing Lead with Mundipharma International, Greg successfully led 26 European countries through the pre-launch and launch phases for a novel pain medication. Greg has held leadership roles at large multinationals (J&J and CSL) and publicly-listed biotech start-ups.